新聞

July 2025

台灣肝癌早期診斷率落後日本逆轉關鍵在定期腹超

肝臟是否健康不能靠感覺，須賴定期抽血、腹部超音波。醫師指出，篩檢推廣多年，民眾意願仍不高，使台灣肝癌早期診斷僅44.5%，低於日本65.7%，也使肝癌末期與死亡率偏高 | 中央通訊社

醫學震撼彈！思覺失調症成因新發現科學家在大腦保護層找到病毒

約翰霍普金斯大學團隊發現，思覺失調症與躁鬱症患者的腦膜中，竟帶有C型肝炎病毒 (HCV) 的痕跡。這項研究顛覆過去對精神疾病起因的理解，顯示部分症狀可能與潛在感染有關。研究已刊登於醫學期刊《Translational Psychiatry》| 自由健康網

消除C肝可望達標國健署：肝癌擬納第7癌公費篩檢

台灣肝臟研究暨教育基金會與聯合報健康事部於22日舉辦「看見台灣─ 台灣正走在消除C肝的路上」專家會議。衛福部國健署長吳昭軍承諾，下半年將放寬成人健檢B、C肝篩檢年齡至39歲，同時研擬將肝癌篩檢納為第7癌篩檢 | 聯合新聞網

免等到45歲 B、C肝公費篩檢擴大 8月起滿39歲就能免費篩

國民健康署昨指出，自8月1日起，將擴大公費肝炎篩檢對象，從原本的45至79歲，下修至1986年以前出生者，也就是年滿39歲即可接受終身一次免費B、C肝篩檢，預估約增200萬人受惠 | 自由健康網

Trump Admin Creates Hepatitis C Care Model, Releases $100M Pilot Funding Opportunity

The Department of Health and Human Services (HHS) is launching an integrated care model to tackle hepatitis C, Secretary Robert F. Kennedy Jr. announced in a news release Monday | Fierce Healthcare

醫學震撼彈！思覺失調症成因新發現科學家在大腦保護層找到病毒

約翰霍普金斯大學團隊發現，思覺失調症與躁鬱症患者的腦膜中，竟帶有C型肝炎病毒 (HCV) 的痕跡。這項研究顛覆過去對精神疾病起因的理解，顯示部分症狀可能與潛在感染有關。研究已刊登於醫學期刊《Translational Psychiatry》| 自由健康網

May 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB) | Business Wire

Gilead Pays Partner Hookipa $10M to Take Over HBV, HIV Therapeutic Vaccine Programs

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma | Fierce Biotech

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB) | Business Wire

Vir's 'Functional Cure' Candidate for Hepatitis B Misses Mark In Phase 2

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the efficacy results hoped for in a midstage study | Fierce Biotech

GSK Posts Phase 3 Itch Data As It Closes In on FDA Approval

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary endpoint | Fierce Biotech

Roche Launches Fibrosis Blood Test for Gauging Liver Disease Severity

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic dysfunction-associated steatotic liver disease, or MASLD | Fierce Medtech

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB) | Business Wire

April 2025

Ipsen's Liver Disease Drug Iqirvo Off to Promising Launch In Battle With Gilead's Livdelzi

Ipsen’s Iqirvo is off to a solid start with sales of 23 million euros ($26 million) in the first quarter of this year as it battles for market share with two other drugs - one old and one new - to treat patients with the rare liver disease primary biliary cholangitis (PBC) | Fierce Pharma

清除國病 B、C肝篩檢擬放寬至40歲國健署：逾百萬人受惠

國民健康署長吳昭軍昨透露，國健署正研擬將現行45至70歲的B、C型肝炎篩檢對象，提前至40歲，預計投入約3億元、超過100萬人受惠，力拚今年7月上路 | 自由健康網

March 2025

Surrozen Drops Sole Clinical-stage Drug Over Weak Hepatitis Data, Pivots to Eye Disease

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the hepatitis drug failed to prove its worth in an early-stage trial | Fierce Biotech

B型及C型肝炎併發代謝異常增加死亡風險及肝癌機率－臺大醫院最新研究榮登《肝病學雜誌》

臺大醫院肝炎團隊的研究成果揭示了B型與C型肝炎患者合併代謝異常的風險，並對未來的治療及預防策略提出了重要見解。該研究成果已於國際頂尖期刊《肝病學雜誌》 (Journal of Hepatology) 發表，引發全球醫學界高度關注 | 長春月刊

Daiichi Taps Nosis to Deliver RNA Therapies Beyond The Liver

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver | Fierce Biotech

Atea Offloads A Quarter of Its Workforce, Gears Up for Phase 3 HCV Trials

Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a phase 3 trial of its hepatitis C cocktail, a combination of the nucleotide analog polymerase inhibitor bemnifosbuvir and the NS5A inhibitor ruzasvir, which hit the primary endpoints of safety and sustained virologic response in a phase 2 trial in December 2024 | Fierce Biotech

February 2025

B、C型肝炎合併代謝異常，台大研究：罹癌、死亡風險增

台大醫院日前公布兩項針對B、C型肝炎的最新研究，研究發現，B型肝炎患者若同時合併三種以上代謝疾病，死亡風險將攀升至兩倍以上；但若僅有「單純脂肪肝」，死亡風險反而下降。另一項研究則指出，C型肝炎患者若合併「代謝異常脂肪肝病」，即使清除病毒後，罹患肝細胞癌的風險仍較高 | 長春月刊

Vir, Awaiting 'Functional Cure' Data for Hep B Combo, Won't Take Treatment Forward Alone

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner | Fierce Biotech

B、C型肝炎合併代謝異常，台大研究：罹癌、死亡風險增

台大醫院日前公布兩項針對B、C型肝炎的最新研究，研究發現，B型肝炎患者若同時合併三種以上代謝疾病，死亡風險將攀升至兩倍以上；但若僅有「單純脂肪肝」，死亡風險反而下降。另一項研究則指出，C型肝炎患者若合併「代謝異常脂肪肝病」，即使清除病毒後，罹患肝細胞癌的風險仍較高 | 長春月刊

2025消除C肝最後一哩路加強受刑人篩檢預估6千人受惠

國健署長吳昭軍表示，為揪出潛在患者，國健署與法務部矯正署合作推動C肝篩檢，讓受刑人也能接受治療計畫，估計可嘉惠6000人 | 聯合新聞網

GSK Drops One Potential 'Functional Cure' for Hep B As It Goes All-in On Bepirovirsen

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential functional cure, GSK3528869, for the infectious disease | Fierce Biotech

B肝治療新突破台韓跨國研究登上國際醫學期刊「刺胳針」

高雄醫學大學校長余明隆攜手韓國蔚山大學醫學院院長林永錫教授及Jonggi Choi教授合作發表研究成果登上國際醫學期刊「刺胳針胃腸肝膽學」| 聯合新聞網

B、C型肝炎合併代謝異常，台大研究：罹癌、死亡風險增

台大醫院日前公布兩項針對B、C型肝炎的最新研究，研究發現，B型肝炎患者若同時合併三種以上代謝疾病，死亡風險將攀升至兩倍以上；但若僅有「單純脂肪肝」，死亡風險反而下降。另一項研究則指出，C型肝炎患者若合併「代謝異常脂肪肝病」，即使清除病毒後，罹患肝細胞癌的風險仍較高 | 長春月刊

January 2025

FDA Grants Breakthrough Status to Bluejay’s Brelovitug

The US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug, to treat chronic hepatitis delta (CHD) | Pharmaceutical Technology

Epigenetic Biotech Raises Bumper Round to The Tune of $175M to Fund Entry into Clinic

Tune Therapeutics has spent recent months securing permission to bring Tune-401 into clinical trials in both New Zealand and Hong Kong. The epigenetic silencing drug for chronic hepatitis B (HBV) is built on Tune’s TEMPO epigenetic editing platform, which is delivered to cells in lipid nanoparticles | Fierce Biotech

December 2024

台灣宣誓2025消除C肝國際預評連讚「三冠王」有望達標

台灣宣誓2025年消除C肝，今「全球消除肝炎聯盟 The Coalition for Global Hepatitis Elimination, CGHE」與歐、美、日、澳等專家來台預評，對於台灣篩檢率、治療率、每年提供每位靜脈藥癮者清潔針具數三項指標，給予金牌認證，認為「三冠王」的成績有助台灣早於世衛組織目標前消除C肝 | 聯合新聞網

B肝疫苗抗體10年後消退可自費接種追加

40歲以上的民眾，如未曾感染過，且表面抗原及抗體陰性，建議自費打1劑B肝疫苗。如無法順利產生抗體，則建議完成3劑療程 | 自由健康網

瞄準2025消除C肝加強3族群篩檢治療防再感染

衛福部長邱泰源表示，經擴大篩檢、健保給付等措施，明年有信心達標，更瞄準世衛金牌認證，最後一哩路將加強慢性病共病患者以及藥癮者、監獄受刑者的篩檢與治療，防止再度感染 | 中央社

台灣宣誓2025消除C肝國際預評連讚「三冠王」有望達標

台灣宣誓2025年消除C肝，今「全球消除肝炎聯盟 The Coalition for Global Hepatitis Elimination, CGHE」與歐、美、日、澳等專家來台預評，對於台灣篩檢率、治療率、每年提供每位靜脈藥癮者清潔針具數三項指標，給予金牌認證，認為「三冠王」的成績有助台灣早於世衛組織目標前消除C肝 | 聯合新聞網

4肝癌危險因子，男性、年紀大入列，定期追蹤是避免復發的關鍵

B肝帶原者為什麼會罹患肝癌，蕭敦仁醫師列出以下數種危險因子，包含e抗原陽性或陰性、病毒量的濃度高低、GPT正不正常、以及有沒有產生肝硬化 | 長春月刊

GSK Axes Hepatitis B Vaccine Trial After Missing Efficacy Goal

GSK has terminated a phase 1/2 hepatitis B trial after the therapeutic vaccine regimen failed to meet the efficacy endpoint, denting the company’s hopes of creating a functional cure for the infectious disease | Fierce Biotech

台灣宣誓2025消除C肝國際預評連讚「三冠王」有望達標

台灣宣誓2025年消除C肝，今「全球消除肝炎聯盟 The Coalition for Global Hepatitis Elimination, CGHE」與歐、美、日、澳等專家來台預評，對於台灣篩檢率、治療率、每年提供每位靜脈藥癮者清潔針具數三項指標，給予金牌認證，認為「三冠王」的成績有助台灣早於世衛組織目標前消除C肝 | 聯合新聞網

November 2024

口服Ｃ肝新藥12週　單親媽媽意外緩解憂鬱症！

雙和醫院胃腸肝膽科胡炳任醫師解釋，逾半數的慢性Ｃ肝者會在病程發展中合併肝外症候群，可能導致糖尿病、慢性腎病變、淋巴癌、甲狀腺功能異常、憂鬱焦慮等情感性疾患出現 | 健康醫療網

Viking Pads Case For MASH Drug With Final Ph. 2 Data Showing Significant Reductions In Liver Fibrosis

Patients taking the highest two doses, 5 mg and 10 mg, saw their liver fibrosis improve by 44% to 57% after 52 weeks, compared to 34% for the placebo group | Fierce Biotech

GSK Scratches Itch For Phase 3 Win, Hitting Goal In Liver Disease Trial To Open Up Untapped Market

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some patients | Fierce Biotech

VBI Vaccines Recalls Hepatitis B Shot As It Winds Down Operations

VBI Vaccines is winding down U.S. operations and requested destruction of all remaining PreHevbrio vial | Fierce Pharma

FDA Hits Kezar's Zetomipzomib Program With 2nd Clinical Hold In 2 Months

The FDA issued the partial hold in the wake of the agency’s full hold last month on the PALIZADE trial | Fierce Biotech

October 2024

台B肝死亡率高於亞洲各國立院厚生會籲制定國家政策

立法院厚生會跨黨派立委今日共同舉行記者會，指根據「全球肝炎消除聯盟」的數據，台灣每10萬人B型肝炎的死亡率為22人，高於周遭亞洲國家，呼籲衛生福利部應儘速盤點國內B型肝炎的帶原人數，並比照滅除C型肝炎制定國家政策 | 自由健康網

全球首例! Precision BioSciences啟動慢性B型肝炎基因治療人體試驗

Precision BioSciences 獲東歐國家摩爾多瓦監管機構批准，展開針對慢性B型肝炎的基因治療人體試驗 | 環球生技月刊

Rectify's New Lead Candidate Improves Bile Composition, Reduces Inflammation In Mice With Liver Disease

Rectify Pharma calls its new lead candidate a "pipeline-in-a-pill" because of its potential to treat the underlying cause of multiple liver diseases | Fierce Biotech

台B肝死亡率高於亞洲各國立院厚生會籲制定國家政策

立法院厚生會跨黨派立委今日共同舉行記者會，指根據「全球肝炎消除聯盟」的數據，台灣每10萬人B型肝炎的死亡率為22人，高於周遭亞洲國家，呼籲衛生福利部應儘速盤點國內B型肝炎的帶原人數，並比照滅除C型肝炎制定國家政策 | 自由健康網

立院厚生會籲政府擴大B肝C肝篩檢納入勞工健檢項目

肝病曾被喻為「國病」，長久以來位居10大癌症死因排行榜第2名，B、C型肝炎是致病的主要原因。立法院厚生會呼籲，政府應將1986年前出生的人納入公費肝炎篩檢，找出更多B、C肝帶原者，並將B、C肝炎篩檢納入勞工健檢項目 | NOW健康

Gilead Gives Up On $15M MASH Bet With Yuhan After Mulling Preclinical Data

One of the candidates demonstrated "strong anti-inflammatory and anti-fibrotic efficacy in the preclinical setting," Gilead said | Fierce Biotech

台B肝死亡率高於亞洲各國立院厚生會籲制定國家政策

立法院厚生會跨黨派立委今日共同舉行記者會，指根據「全球肝炎消除聯盟」的數據，台灣每10萬人B型肝炎的死亡率為22人，高於周遭亞洲國家，呼籲衛生福利部應儘速盤點國內B型肝炎的帶原人數，並比照滅除C型肝炎制定國家政策 | 自由健康網

September 2024

C型肝炎疫苗曙光？科學家揭開病毒感染之謎

科學家們近期揭開了C型肝炎病毒感染細胞的奧秘，這項突破性研究為研發疫苗帶來希望，可能終結這項全球性疾病 | 自由健康網

Ipsen’s Iqirvo wins European approval for primary biliary cholangitis - Pharmaceutical Technology

The approval sets up a showdown between Iqirvo and Intercept’s PBC treatment Ocaliva | Pharmaceutical Technology

Aligos' MASH Prospect Slashes Liver Fat In Phase 2, But Stock Drops Anyway

Aligos Therapeutics has announced a midstage metabolic-dysfunction associated steatohepatitis win, though questions remain about data totality and financing for further development | Fierce Biotech

Intercept's Liver Med Ocaliva Takes Heat At FDA Expert Meeting, As Hopes For Full Approval Dim

Ocaliva initially won an accelerated green light in the U.S. in 2016 for PBC, a rare disease of the liver in which the bile ducts become inflamed and are slowly destroyed | Fierce Pharma

Ocaliva Approval In Europe Withdrawn Following Data Re-assessment

Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment | Pharmaceutical Technology

August 2024

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA | Gilead Sciences Inc.

With FDA Approval of Livdelzi, Gilead Launches An Inflammatory Drug For The First Time

With an FDA approval in hand for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar), Gilead Sciences enters arenas that are both new and old | Fierce Pharma

年輕學者突破HIV防治困境：C肝、性病、糖尿病研究成果豐碩

吉立亞醫藥「HIV領域研究學者計畫」獲獎名單出爐，近年來台灣多名年輕感染科醫師分別投入於C肝防治、性病治療、糖尿病預防等臨床研究，獲得肯定 | 元氣網

嘉義六腳衛生所推「3+1行動醫療」打造健康平等入圍健康城市評選

嘉義縣六腳鄉衛生所以「3+1行動醫療服務」實際運作模式，充分展現行動醫療團隊健康服務一條龍超能力 | 風傳媒

兒童也可能罹患A肝、B肝、脂肪肝！呵護小心肝，護肝保健從小著手

兒童也可能罹患肝炎如A肝、B肝，還有兒童脂肪肝問題也別輕忽 | PChome Online

預防B肝寶寶台灣垂直感染率降至1.2％低於世衛標準

B型肝炎至今仍是國人肝病的一大主因，其中母嬰垂直傳染是常見的傳染途徑。專家提醒，針對高風險孕婦的治療與給付政策已到位，希望透過推廣降低感染率 | 自由健康網

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA | Gilead Sciences Inc.

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA | Gilead Sciences Inc.

July 2024

消除C肝論壇／跨界合作特殊族群篩檢率增

在台灣消除Ｃ肝的過程中，靜脈毒癮者與矯正機關收容人等族群，不僅易因共用針頭感染Ｃ肝，且因篩檢不易常成「漏網之魚」。這些族群雖是Ｃ肝高危險群卻無法強制篩檢，且用藥順從度較差、再感染率也較高，因此需靠衛教、效率與跨團隊合作，進行Ｃ肝防治 | 聯合新聞網

徹底消除B肝病毒感染台灣有望同步全球「放寬B肝治療」

WHO、中國、美國皆研擬放B肝治療條件，期能消除B肝 | 健康醫療網

消除C肝論壇／高危險群防再感染C肝

「Ｃ肝治癒後，避免再感染」是專家認為的重要課題 | 聯合新聞網

消除C肝論壇／跨界合作特殊族群篩檢率增

在台灣消除Ｃ肝的過程中，靜脈毒癮者與矯正機關收容人等族群，不僅易因共用針頭感染Ｃ肝，且因篩檢不易常成「漏網之魚」。這些族群雖是Ｃ肝高危險群卻無法強制篩檢，且用藥順從度較差、再感染率也較高，因此需靠衛教、效率與跨團隊合作，進行Ｃ肝防治 | 聯合新聞網

消除C肝論壇／慢性病患C肝普篩降併發症風險

政府已將糖尿病、腎臟病等慢性病患列為Ｃ肝普篩對象，期及早篩出治療 | 聯合新聞網

B肝疫苗要不要補打？食藥署建議高風險族群追加

食藥署建議，高風險患者可自費追加1劑疫苗，一般民眾則無需施打追加劑 | 自由健康網

消除C肝論壇／跨界合作特殊族群篩檢率增

在台灣消除Ｃ肝的過程中，靜脈毒癮者與矯正機關收容人等族群，不僅易因共用針頭感染Ｃ肝，且因篩檢不易常成「漏網之魚」。這些族群雖是Ｃ肝高危險群卻無法強制篩檢，且用藥順從度較差、再感染率也較高，因此需靠衛教、效率與跨團隊合作，進行Ｃ肝防治 | 聯合新聞網

June 2024

根除C肝進度「台灣成亞洲標竿」　衛福部加碼！篩檢費調高至370元

專家呼籲45至79歲民眾，以及糖尿病、腎臟病、高血脂患者，應主動抽血檢驗瞭解有無感染C型肝炎 | CTWANT

根除C肝待揪4萬患者治療醫：濁水溪以北是關鍵

台灣有望明年提早達標「C肝根除」，但國內仍有約4萬名C肝感染者不自知，找出患者進行治療是根除的最後一哩路。醫師點名濁水溪以北的縣市是關鍵，呼籲主動篩檢 | 中央社 CNA

FDA首批C肝POCT檢測！丹納赫旗下Cepheid測病毒RNA 結果一小時出爐

丹納赫(Danaher)集團旗下診斷設備商Cepheid宣布，其C型肝炎檢測工具Xpert HCV和GeneXpert Xpress系統，獲得美國食品藥物管理局 (FDA) De Novo醫材審查核准，成為FDA核可的第一款C肝病毒定點照護檢驗 (POCT) 產品 | 環球生技月刊

2025 根除 C 肝！「一腎三高」是 C 肝中度風險族群積極篩檢早治療

治療C肝同時改善糖尿病、慢性腎病及中風風險 | HEHO健康網

嘉義縣府攜手長庚醫療團隊協助追蹤盼消除C肝

嘉義縣六腳鄉、義竹鄉C型肝炎盛行率為全縣最高，衛生局與長庚醫療團隊合作，22日在義竹鄉舉辦肝炎篩檢，協助民眾定期追蹤 | 中央社 CNA

May 2024

Investigational Seladelpar Demonstrates Significant Improvements In Liver Disease Progression And Reduced Itching In Primary Biliary Cholangitis

Gilead Sciences announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. | Gilead Sciences, Inc.

南投藥癮戒治機構協助藥癮者C肝篩檢及治療

配合衛生福利部提出2025年革除C肝計畫，南投毒防中心補助藥癮者進行戒癮治療時的相關檢查與治療 | 台灣好報

B肝病毒新發現！科學家破解聚合酶蛋白機制根治有望

美國洛克斐勒大學 (Rockefeller University) 賴斯實驗室 (Laboratory of Virology and Infectious Disease) 的研究助理教授史奈德 (Bill Schneider) 博士領導的研究團隊，揭示了B肝病毒的新機制，為開發根治B肝的新療法開闢了道路 | 自由健康網

肝病權威余明隆專訪3-1》

對抗C肝逾30年創新治療引領全球 | 自由健康網

肝病權威余明隆專訪3-2》

力拚2025消除C肝年底邀WHO代表來台商議 | 自由健康網

肝病權威余明隆專訪3-3》

消除C肝有望！揭肝病防治未來2大重點 | 自由健康網

Investigational Seladelpar Demonstrates Significant Improvements In Liver Disease Progression And Reduced Itching In Primary Biliary Cholangitis

Gilead Sciences announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. | Gilead Sciences, Inc.

Investigational Seladelpar Demonstrates Significant Improvements In Liver Disease Progression And Reduced Itching In Primary Biliary Cholangitis

Gilead Sciences announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. | Gilead Sciences, Inc.

April 2024

公費篩檢健保給付防肝癌

明知BC肝卻不就醫達3成 | 中央社 CNA

消除B、C肝炎要趁早國健署提供45-79歲免費篩檢

國健署提供45至79歲民眾（原住民提早至40歲）終身1次免費的B、C型肝炎篩檢服務，建議符合資格民眾，盡早檢查，以便及早治療 | 自由健康網

北榮桃園分院跨團隊攜手「消滅C型肝炎」

C型肝炎是透過血液傳播的疾病，藥癮靜脈注射者在使用海洛因靜脈注射時，常常因共用針具和稀釋液而間接感染到C型肝炎 | 大紀元新聞網

健保署攜手義大醫院聯手提升澎湖離島在地醫療

配合國家2025年C型肝炎根除計畫，義大醫院與中央健康保險署、澎湖縣政府衛生局和當地衛生所積極合作進行B、C肝篩檢活動 | 今傳媒

公費篩檢健保給付防肝癌明知BC肝卻不就醫達3成

台灣肝癌病人超過8成感染B型或C型肝炎病毒，當慢性病毒性肝炎未治療，極可能惡化為肝硬化、肝癌；然而，即使台灣提供可近性高的公費肝病篩檢，知道自己有B型肝炎或C型肝炎的民眾仍有3成未就醫 | 中央社CNA

March 2024

台塑麥寮鄰近5鄉疾病篩檢起跑 17項檢查全免費

麥寮鄰近5鄉居民疾病預防篩檢，檢查項目包括肝炎、慢性阻塞性肺病、代謝症候群、腎功能等17項

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Efficacy and safety profile of once-daily Vemlidy demonstrated in children six years of age (weighing at least 25kg) and older | Gilead Sciences, Inc.

Altimmune Bails on Hepatitis B After Phase 2 Data Disappoint

Altimmune has been beaten by hepatitis B. The drug candidate, which the company was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech to stop development and focus on its GLP-1/glucagon dual receptor agonist | FIERCE Biotech

Gilead Sciences Announces Completion of Acquisition of CymaBay

Gilead Sciences Announces Completion of Acquisition of CymaBay | Gilead Sciences, Inc.

剔除錯誤基因「貼上」正確 DNA 片段！

「基因編輯」有治癒 B 型肝炎的潛力 | HEHO健康網

This website is non-promotional and intended to provide scientific information to healthcare professionals. The content provided on this website has undergone strict internal medical review and is regularly updated to reflect new information.

We do not make any clinical recommendations or provide any medical treatment advice or opinions. Any information provided on this website regarding currently available treatment options should not, in any way, take the place of a physician's medical judgement.

This website is intended for use in Taiwan only. Other countries may have different regulatory requirements and review practices that may require referencing different information. If you are a resident of another country, please see our worldwide locations to find information about your country. The product information provided on this website is intended only for healthcare professionals in Taiwan. The products discussed here may have different approved labeling in other countries. Please refer to the full prescribing information for approved product labeling and important safety information in your country. As registration conditions and prescribing information differ internationally, you must always consult your local prescribing information.

powered by feversocial

icon_BackToTop